Skip to main content
. Author manuscript; available in PMC: 2021 Oct 13.
Published in final edited form as: Immunity. 2020 Sep 24;53(4):852–863.e7. doi: 10.1016/j.immuni.2020.08.015

Figure 1. Broadly cross-reactive anti-neuraminidase monoclonal antibodies.

Figure 1.

(A) Specificities of 21 clonally distinct mAbs, IGHV and IGLV gene usage, and amino acid sequence of the heavy chain CDR3 for each BNA-mAb.

(B) ELISA of binding by seven BNA-mAbs plus an IBV HA-specific mAb (2B04) to recombinant NA and HA from the indicated IBV strains. Data are representative of two experiments. See also Figure S1 and Tables S1 and S2.